公募基金方面，本期较上一期持股增加的公募基金共计1个，即医疗器械ETF，持股增加占比达0.12%。 本期较上一季未再披露的公募基金共计138个，主要包括招商中证全指医疗器械ETF、建信中证全指医 疗保健设备与服务ETF、医服ETF、汇添富中证全指医疗器械ETF、南方中证全指医疗保健设备与服务 ETF等。 2025年10月31日，健尔康(603205.SH)发布2025年第三季报。截至2025年10月30日，共有4个机构投资者 披露持有健尔康A股股份，合计持股量达1315.51万股，占健尔康总股本的8.43%。其中，机构投资者包 括常州和聚实业投资合伙企业(有限合伙)、常州顺赢实业投资合伙企业(有限合伙)、常州清源知创创业 投资合伙企业(有限合伙)、招商银行股份有限公司-永赢中证全指医疗器械交易型开放式指数证券投资基 金，机构投资者合计持股比例达8.43%。相较于上一季度，机构持股比例合计下跌了0.12个百分点。 ...

Core Viewpoint - Meikang Bio (300439.SZ) reported its Q3 2025 results, highlighting a slight increase in institutional ownership and changes in public fund holdings [1] Institutional Investors - As of October 28, 2025, two institutional investors disclosed holdings in Meikang Bio A-shares, totaling 41.41 million shares, which represents 10.78% of the total share capital [1] - The institutional ownership increased by 0.03 percentage points compared to the previous quarter [1] Public Funds - One public fund, the Medical Device ETF, increased its holdings, contributing to a rise of 0.21% in ownership [1] - A total of 33 public funds did not disclose their holdings in this period, including notable funds such as E Fund CSI Wind Bio-Tech Index (LOF) A and others [1]

Group 1 - The core viewpoint of the news is that Caina Co., Ltd. (301122.SZ) has reported its semi-annual results for 2025, highlighting significant institutional investment in its A-shares [1] - As of August 27, 2025, a total of 12 institutional investors disclosed holdings in Caina Co., Ltd., with a combined shareholding of 33.6289 million shares, representing 27.51% of the total share capital [1] - The top ten institutional investors collectively hold a proportion of 27.51%, which has increased by 0.49 percentage points compared to the previous quarter [1] Group 2 - In terms of public funds, five new public funds were disclosed this period compared to the previous quarter, including Medical Device ETF, China Securities Medical Device ETF, Galaxy Intelligent Mixed A, Galaxy Industrial Power Mixed A, and Galaxy He Mei Life Mixed A [1] - Regarding foreign investment, one new foreign institution was disclosed this period, namely J.P. Morgan Securities PLC - proprietary funds [2]

Core Viewpoint - Guanhao Biological (300238.SZ) reported its semi-annual results for 2025, highlighting a significant presence of institutional investors holding 29.07% of its total shares as of August 27, 2025 [1] Institutional Holdings - A total of 9 institutional investors disclosed their holdings in Guanhao Biological, amounting to 77.0696 million shares, which represents 29.07% of the company's total equity [1] - The institutional holding percentage increased by 0.35 percentage points compared to the previous quarter [1] Public Fund Involvement - Three new public funds were disclosed in this period compared to the previous quarter, including Medical Device ETF, China Securities Index Medical Device ETF, and Ping An CSI 2000 Enhanced Strategy ETF [1] Foreign Investment - One new foreign institution, BARCLAYS BANK PLC, disclosed its holdings this period, while Goldman Sachs LLC was not reported in this quarter [1]

Core Viewpoint - Weigao Orthopedics (688161.SH) reported its semi-annual results for 2025, highlighting significant institutional ownership and changes in investor composition [1] Group 1: Institutional Ownership - As of August 27, 2025, a total of 13 institutional investors disclosed holdings in Weigao Orthopedics A-shares, with a combined holding of 354 million shares, representing 88.62% of the total share capital [1] - The top ten institutional investors collectively hold 88.53% of the shares, with a decrease of 0.75 percentage points compared to the previous quarter [1] Group 2: Specific Investors - The top institutional investors include Shandong Weigao Group Medical Polymer Co., Ltd., Weigao International Medical Co., Ltd., and Weigao Group Co., Ltd. among others [1] - In the public fund sector, two new public funds were disclosed this quarter, including a medical device ETF and the China Merchants CSI All-Index Medical Device ETF [1] - In the insurance investment sector, one new insurance investor was disclosed, namely China Life Insurance Co., Ltd. - Traditional - Ordinary Insurance Product - 005L-CT001 [1]

Group 1 - Berry Genomics (000710.SZ) released its 2024 annual report on April 25, 2025, indicating that as of April 24, 2025, 44 institutional investors disclosed holding A-shares, totaling 79.7934 million shares, which accounts for 22.57% of the total share capital [1] - The top ten institutional investors include Chengdu Tianxing Instrument (Group) Co., Ltd., Hongling Siqi (Zhuhai) M&A Equity Investment Enterprise (Limited Partnership), and others, with a combined holding ratio of 22.43%, reflecting a decrease of 1.55 percentage points compared to the previous quarter [1] - In the public fund sector, 37 new public funds were disclosed this period compared to the previous quarter, including funds such as Huatai-PB CSI Precision Medicine Index (LOF) A and Medical Device ETF [1] Group 2 - Foreign institutional investors that did not disclose holdings this period include MORGAN STANLEY & CO. INTERNATIONAL PLC, BARCLAYS BANK PLC, and J.P. Morgan Securities PLC - proprietary funds [2]